News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Achillion Pharmaceuticals, Inc. (ACHN) Plunges on FDA Hold on Hepatitic C Med


9/30/2013 7:51:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Achillion Pharmaceuticals Inc. (ACHN) plunged as much as 53 percent after U.S. regulators kept the company’s experimental hepatitis C drug sovaprevir on hold because of abnormal liver results. Achillion fell to $3.42 at 7:37 a.m. New York time. The Food and Drug Administration determined the compound’s development shouldn’t resume after the company responded to all the issues raised by the agency in June, New Haven, Connecticut-based Achillion said in a statement after the market closed on Sept. 27.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at News Release
Read at News Release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES